Publication

Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis

van Wijhe, M., de Boer, P. T., de Jong, H. J., van Vliet, H., Wallinga, J. & Postma, M. J., 10-Sep-2019, In : Vaccine. 37, 38, p. 5698-5707 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van Wijhe, M., de Boer, P. T., de Jong, H. J., van Vliet, H., Wallinga, J., & Postma, M. J. (2019). Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis. Vaccine, 37(38), 5698-5707. https://doi.org/10.1016/j.vaccine.2019.07.097

Author

van Wijhe, Maarten ; de Boer, Pieter T. ; de Jong, Herman J. ; van Vliet, Hans ; Wallinga, Jacco ; Postma, Maarten J. / Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis. In: Vaccine. 2019 ; Vol. 37, No. 38. pp. 5698-5707.

Harvard

van Wijhe, M, de Boer, PT, de Jong, HJ, van Vliet, H, Wallinga, J & Postma, MJ 2019, 'Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis', Vaccine, vol. 37, no. 38, pp. 5698-5707. https://doi.org/10.1016/j.vaccine.2019.07.097

Standard

Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis. / van Wijhe, Maarten; de Boer, Pieter T.; de Jong, Herman J.; van Vliet, Hans; Wallinga, Jacco; Postma, Maarten J.

In: Vaccine, Vol. 37, No. 38, 10.09.2019, p. 5698-5707.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van Wijhe M, de Boer PT, de Jong HJ, van Vliet H, Wallinga J, Postma MJ. Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis. Vaccine. 2019 Sep 10;37(38):5698-5707. https://doi.org/10.1016/j.vaccine.2019.07.097


BibTeX

@article{c219fdc02c314a5e847f94e3a3709991,
title = "Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis",
abstract = "BACKGROUND: Health economic evaluations are often required before implementing a vaccination programme. Such evaluations rarely consider the historical context of a vaccination programme. We review the financial history of vaccination programmes in the Netherlands, and compare these to demographic and macroeconomic developments as well as avoided mortality burden.METHODS: Previously uncatalogued historical expenditures on the Dutch National Immunisation Programme (NIP) and influenza vaccination were obtained from official reports. Costs were adjusted for inflation using Consumer Price Indices and expressed in Euro of 2016. Estimates on mortality burden averted were obtained from previous research and used to calculate the ratio of expenses to averted mortality burden for vaccinations against diphtheria, tetanus, pertussis, polio, measles, mumps and rubella for birth cohorts 1953-1992.RESULTS: Developments towards a uniform government funded NIP started early 1950s with vaccinations against diphtheria, pertussis and tetanus, culminating in its official launch in 1957 together with polio vaccinations. Since the 1980s, expenditure increased nearly five-fold mostly due to the addition of new vaccines, while spending on already implemented vaccinations tended to decline. Overall, expenditure increased from € 5 million in 1957 to € 93 million in 2014. Relative to total healthcare expenditure, the NIP contributed little, ranging between 0.05{\%} and 0.14{\%}. Spending on influenza vaccination increased from € 37 million in 1996 to € 52 million in 2014, while relative to total healthcare expenditure it decreased from 0.069{\%} to 0.055{\%}. In 2014, 0.15{\%} of healthcare expenditure and € 533 per birth was spent on vaccination programmes. Overall, for birth cohorts 1953-1992, € 5.4 thousand (95{\%} confidence interval: 4.0-7.3) was expended per year-of-life-lost averted.CONCLUSION: The actual costs per year-of-life gained are more favorable than estimated here since averted medical costs were not included. Although expenditure on vaccination programmes increased substantially, the contribution to overall healthcare expenditure remained small.",
keywords = "INFLUENZA VACCINATION, CONJUGATE VACCINATION, ECONOMIC-EVALUATION, COST-EFFECTIVENESS, UNITED-STATES, VACCINES, HEALTH, IMPACT, MORTALITY, DISEASES",
author = "{van Wijhe}, Maarten and {de Boer}, {Pieter T.} and {de Jong}, {Herman J.} and {van Vliet}, Hans and Jacco Wallinga and Postma, {Maarten J.}",
note = "Copyright {\circledC} 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2019",
month = "9",
day = "10",
doi = "10.1016/j.vaccine.2019.07.097",
language = "English",
volume = "37",
pages = "5698--5707",
journal = "Vaccine",
issn = "0264-410X",
publisher = "ELSEVIER SCI LTD",
number = "38",

}

RIS

TY - JOUR

T1 - Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis

AU - van Wijhe, Maarten

AU - de Boer, Pieter T.

AU - de Jong, Herman J.

AU - van Vliet, Hans

AU - Wallinga, Jacco

AU - Postma, Maarten J.

N1 - Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2019/9/10

Y1 - 2019/9/10

N2 - BACKGROUND: Health economic evaluations are often required before implementing a vaccination programme. Such evaluations rarely consider the historical context of a vaccination programme. We review the financial history of vaccination programmes in the Netherlands, and compare these to demographic and macroeconomic developments as well as avoided mortality burden.METHODS: Previously uncatalogued historical expenditures on the Dutch National Immunisation Programme (NIP) and influenza vaccination were obtained from official reports. Costs were adjusted for inflation using Consumer Price Indices and expressed in Euro of 2016. Estimates on mortality burden averted were obtained from previous research and used to calculate the ratio of expenses to averted mortality burden for vaccinations against diphtheria, tetanus, pertussis, polio, measles, mumps and rubella for birth cohorts 1953-1992.RESULTS: Developments towards a uniform government funded NIP started early 1950s with vaccinations against diphtheria, pertussis and tetanus, culminating in its official launch in 1957 together with polio vaccinations. Since the 1980s, expenditure increased nearly five-fold mostly due to the addition of new vaccines, while spending on already implemented vaccinations tended to decline. Overall, expenditure increased from € 5 million in 1957 to € 93 million in 2014. Relative to total healthcare expenditure, the NIP contributed little, ranging between 0.05% and 0.14%. Spending on influenza vaccination increased from € 37 million in 1996 to € 52 million in 2014, while relative to total healthcare expenditure it decreased from 0.069% to 0.055%. In 2014, 0.15% of healthcare expenditure and € 533 per birth was spent on vaccination programmes. Overall, for birth cohorts 1953-1992, € 5.4 thousand (95% confidence interval: 4.0-7.3) was expended per year-of-life-lost averted.CONCLUSION: The actual costs per year-of-life gained are more favorable than estimated here since averted medical costs were not included. Although expenditure on vaccination programmes increased substantially, the contribution to overall healthcare expenditure remained small.

AB - BACKGROUND: Health economic evaluations are often required before implementing a vaccination programme. Such evaluations rarely consider the historical context of a vaccination programme. We review the financial history of vaccination programmes in the Netherlands, and compare these to demographic and macroeconomic developments as well as avoided mortality burden.METHODS: Previously uncatalogued historical expenditures on the Dutch National Immunisation Programme (NIP) and influenza vaccination were obtained from official reports. Costs were adjusted for inflation using Consumer Price Indices and expressed in Euro of 2016. Estimates on mortality burden averted were obtained from previous research and used to calculate the ratio of expenses to averted mortality burden for vaccinations against diphtheria, tetanus, pertussis, polio, measles, mumps and rubella for birth cohorts 1953-1992.RESULTS: Developments towards a uniform government funded NIP started early 1950s with vaccinations against diphtheria, pertussis and tetanus, culminating in its official launch in 1957 together with polio vaccinations. Since the 1980s, expenditure increased nearly five-fold mostly due to the addition of new vaccines, while spending on already implemented vaccinations tended to decline. Overall, expenditure increased from € 5 million in 1957 to € 93 million in 2014. Relative to total healthcare expenditure, the NIP contributed little, ranging between 0.05% and 0.14%. Spending on influenza vaccination increased from € 37 million in 1996 to € 52 million in 2014, while relative to total healthcare expenditure it decreased from 0.069% to 0.055%. In 2014, 0.15% of healthcare expenditure and € 533 per birth was spent on vaccination programmes. Overall, for birth cohorts 1953-1992, € 5.4 thousand (95% confidence interval: 4.0-7.3) was expended per year-of-life-lost averted.CONCLUSION: The actual costs per year-of-life gained are more favorable than estimated here since averted medical costs were not included. Although expenditure on vaccination programmes increased substantially, the contribution to overall healthcare expenditure remained small.

KW - INFLUENZA VACCINATION

KW - CONJUGATE VACCINATION

KW - ECONOMIC-EVALUATION

KW - COST-EFFECTIVENESS

KW - UNITED-STATES

KW - VACCINES

KW - HEALTH

KW - IMPACT

KW - MORTALITY

KW - DISEASES

U2 - 10.1016/j.vaccine.2019.07.097

DO - 10.1016/j.vaccine.2019.07.097

M3 - Article

VL - 37

SP - 5698

EP - 5707

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 38

ER -

ID: 95095705